Action Zafgen - ZFGN

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

0,99

Prix Achat

0,9801

Prix Vente

0,99

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

43,467M

Clôture Veille

0,99

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

43 906 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-1,18

Bénéfice par action (BPA)

-0,84

Chiffre d'affairess

Bénéfice net

-36,95M

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

larimartx.com

Siège social

Wilmington, Delaware, USA

Fondé

Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results

Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates...

Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

Creates clinical-stage company focused on the development of novel protein replacement therapies for rare...

Zafgen Reports Third Quarter 2019 Financial Results

Evaluation of strategic alternatives ongoing BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen...

Zafgen to Explore Strategic Alternatives

BOSTON, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical...

Zafgen Reports Second Quarter 2019 Operating and Financial Results

Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in...

Zafgen to Present at the Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical...

Zafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061

Alignment reached on in vivo animal study design and protocol to translate work from novel in vitro assays and...

Zafgen to Present at the JMP Securities Life Sciences Conference

BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical...

Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific S...

Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced...

Zafgen Announces Regulatory Update on ZGN-1061

Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

ZFGN - Frequently Asked Questions (FAQ)

What is the current Zafgen share price?

The current share price of Zafgen is US$ 0,99

How many Zafgen shares are in issue?

Zafgen has 43 906 000 shares in issue

What is the market cap of Zafgen?

The market capitalisation of Zafgen is USD 43,47M

What is the 1 year trading range for Zafgen share price?

Zafgen has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of Zafgen?

The price to earnings ratio of Zafgen is -1,18

What is the reporting currency for Zafgen?

Zafgen reports financial results in USD

What is the latest annual profit for Zafgen?

The latest annual profit of Zafgen is USD -36,95M

What is the registered address of Zafgen?

The registered address for Zafgen is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the Zafgen website address?

The website address for Zafgen is larimartx.com

Which industry sector does Zafgen operate in?

Zafgen operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
STAKSTAK Inc	US$ 3,97 (156,13%)	174,23k
ORGOOrganogenesis Holdings Inc	US$ 6,21 (102,28%)	59M
TRNRInteractive Strength Inc	US$ 2,57 (67,97%)	193,57M
PMAXPowell Max Ltd	US$ 0,511 (43,54%)	137,18M
ARBBARB IOT Group Ltd	US$ 0,6635 (38,23%)	59,08M
NVNINVNI Group Ltd	US$ 0,99 (-50,50%)	72,79M
SPGCSacks Parente Golf Inc	US$ 0,2085 (-48,65%)	58,21M
ADGMAdagio Medical Holdings Inc	US$ 0,8081 (-47,53%)	756,76k
PRAXPraxis Precision Medicines Inc	US$ 38,60 (-40,64%)	3,2M
SAGSAG Holdings Ltd	US$ 1,19 (-38,97%)	789,86k
NVDANVIDIA Corporation	US$ 124,92 (3,97%)	389,48M
TRNRInteractive Strength Inc	US$ 2,57 (67,97%)	193,57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 13,44 (7,78%)	154,46M
PMAXPowell Max Ltd	US$ 0,511 (43,54%)	137,18M
LCIDLucid Group Inc	US$ 2,22 (-0,45%)	136,17M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Zafgen Inc (ZFGN)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Zafgen Inc

ZFGN Dernières nouvelles

Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results

Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

Zafgen Reports Third Quarter 2019 Financial Results

Zafgen to Explore Strategic Alternatives

Zafgen Reports Second Quarter 2019 Operating and Financial Results

Zafgen to Present at the Wedbush PacGrow Healthcare Conference

Zafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061

Zafgen to Present at the JMP Securities Life Sciences Conference

Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific S...

Zafgen Announces Regulatory Update on ZGN-1061

ZFGN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Zafgen Inc (ZFGN) Cours

Zafgen Inc (ZFGN)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Zafgen Inc

ZFGN Dernières nouvelles

Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results

Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

Zafgen Reports Third Quarter 2019 Financial Results

Zafgen to Explore Strategic Alternatives

Zafgen Reports Second Quarter 2019 Operating and Financial Results

Zafgen to Present at the Wedbush PacGrow Healthcare Conference

Zafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061

Zafgen to Present at the JMP Securities Life Sciences Conference

Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific S...

Zafgen Announces Regulatory Update on ZGN-1061

ZFGN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS